Company
Karolinska Development AB
Headquarters: Solna, Sweden
Employees: 7
CEO: Mr. Johan Dighed
Market Cap
kr472.5 Million
SEK as of Jan. 1, 2024
US$46.9 Million
Karolinska Development AB Categories
Sweden Healthcare BiotechnologySweden Healthcare Sweden Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Karolinska Development AB has the following listings and related stock indices.
Stock: OMX: KDEV wb_incandescent
Stock: FSX: 2I9 wb_incandescent